| Abstrakt: |
A recent study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, explored the combination of chimeric antigen receptor T-cell (CAR-T) therapy with autologous stem cell transplantation (ASCT) in patients with relapsed/refractory B-cell lymphoma. The study found that the combination of CAR-T with ASCT did not increase the incidence of severe cytokine release syndrome (CRS) or neurotoxicity (CRES). However, the incidence of overall CRS and mild CRS was higher in the CAR-T combined with ASCT group compared to the CAR-T alone group. Female patients had a lower incidence of severe CRS but a higher incidence of severe CRES. The study suggests that the combination of ASCT with CAR-T may be a preferable treatment option for relapsed/refractory B-cell lymphoma. [Extracted from the article] |
